Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive

被引:7
作者
Han, Leo [1 ]
Jensen, Jeffrey T. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA
基金
比尔及梅琳达.盖茨基金会;
关键词
combined oral contraceptive; cycle regulation; drospirenone; ethinyl estradiol; flexible extended regimen; Flexyess; menstrual bleeding; oral contraceptive pills; COMBINED ORAL-CONTRACEPTIVES; G/DROSPIRENONE; 3; MG; VENOUS THROMBOEMBOLISM; OPEN-LABEL; DIFFERENT PROGESTOGENS; ACTIVE SURVEILLANCE; WOMEN; ETHINYLESTRADIOL; RISK; MULTICENTER;
D O I
10.1517/14656566.2014.949237
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Introduction: Oral contraceptives are often prescribed in extended or continuous forms in order to manage menstrual bleeding and menstrual-related side effects. However, with extended regimens, unscheduled intracycle bleeding can become problematic. Flexible extended dosing of a contraceptive containing drospirenone (DRSP) and ethinyl estradiol (EE) was designed to improve bleeding profiles during extended cycles through active management of bleeding symptoms. Areas covered: We examine the rationale for flexible extended dosing as well as review the dosing regimen. We will focus on the findings of the two most important clinical trials regarding flexible extended DRSP/EE (3 mg/20 mu g), including the bleeding profiles of women in those trials. Pharmacology, mechanisms of action, efficacy as well as safety of DRSP containing pills will also be reviewed. Expert opinion: Flexible extended dosing of DRSP/EE (3 mg/20 mu g) has similar pharmacokinetics and contraceptive efficacy of both conventional and fixed extended regimens. However, it has the added benefit of fewer days of bleeding/spotting compared to conventional and fixed extended regimens.
引用
收藏
页码:2071 / 2079
页数:9
相关论文
共 39 条
[1]
A multicenter, randomized study of an extended cycle oral contraceptive [J].
Anderson, FD ;
Hait, H .
CONTRACEPTION, 2003, 68 (02) :89-96
[2]
Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo [J].
Anderson, Freedolph D. ;
Feldman, Robert ;
Reape, Kathleen Z. .
CONTRACEPTION, 2008, 77 (02) :91-96
[3]
Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives [J].
Andrist, LC ;
Arias, RD ;
Nucatola, D ;
Kaunitz, AM ;
Musselman, BL ;
Reiter, S ;
Boulanger, J ;
Dominguez, L ;
Emmert, S .
CONTRACEPTION, 2004, 70 (05) :359-363
[4]
Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results [J].
Archer, David F. ;
Jensen, Jeffrey T. ;
Johnson, Julia V. ;
Borisute, Hannah ;
Grubb, Gary S. ;
Constantine, Ginger D. .
CONTRACEPTION, 2006, 74 (06) :439-445
[5]
Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives [J].
Archer, David F. .
CONTRACEPTION, 2006, 74 (05) :359-366
[6]
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone [J].
Bachmann, G ;
Sulak, PJ ;
Sampson-Landers, C ;
Benda, N ;
Marr, J .
CONTRACEPTION, 2004, 70 (03) :191-198
[7]
Bayer Healthcare Pharmaceuticals, 2012, YAZ PRESCR INF
[8]
Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use [J].
den Tonkelaar, I ;
Oddens, BJ .
CONTRACEPTION, 1999, 59 (06) :357-362
[9]
Steady-state phamiacokinetics of an extended-regimen oral contraceptive with continuous estrogen [J].
DiLiberti, Charles E. ;
O'Leary, Christine M. ;
Hendy, Christopher H. ;
Waters, Donald H. ;
Margolis, Marya B. .
CONTRACEPTION, 2011, 83 (01) :55-61
[10]
Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives [J].
Dinger, Juergen ;
Bardenheuer, Kristina ;
Heinemann, Klaas .
CONTRACEPTION, 2014, 89 (04) :253-263